Regulation of the renin-angiotensin system in coronary atherosclerosis: A review of the literature

Vascular Health and Risk Management

Volumn 3, Issue 6, 2007, Pages 937-945

  Hammoud, Ramadan A ^a   Vaccari, Christopher S ^a   Nagamia, Sameer H ^a   Khan, Bobby V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Atherosclerosis; Endothelium; Inflammation; Vasculature

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; ATORVASTATIN; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; NATEGLINIDE; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; RENIN INHIBITOR; RESERPINE; TELMISARTAN; TEMOCAPRIL; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

ACUTE HEART INFARCTION; ANGIONEUROTIC EDEMA; ATHEROGENESIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; COUGHING; DIABETES MELLITUS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LOW DRUG DOSE; MEDICAL LITERATURE; METABOLIC SYNDROME X; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SECONDARY PREVENTION; TISSUE SPECIFICITY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; GLUCOSE; HUMANS; LIPID METABOLISM; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 38149029057     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. [ALLHAT] The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. 2002. Major outcomes high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288:2981-97.
2. Al-Mallah M, Tleyjeh I, Abdel-Latif A, et al. 2006. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function. J Am Coll Cardiol, 47:1576-83.
3. Andersen S, Schalkwijk CG, Stehouwer CD, et al. 2000. Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy. Diabetes Care, 23:1031-2.
4. Collins R, Peto R, MacMahon S, et al. 1990. Blood pressure stroke and coronary heart disease. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet, 335:827-38.
5. Cushman DW, Wang FL, Fung WC, et al. 1989. Differentiation of angiotensin converting enzyme inhibitors (ACE) by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens, 2:294-306.
6. Cusi K, Maezono K, Osman A, et al. 2000. Insulin resistance differentially affects the PI3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest, 105:311-20.
7. Dahlöf B, Devereux RB, Kjeldsen SE, et al. 2002. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet, 359:995-1003.
8. [DREAM] The DREAM (Diabetes reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. 2006. Effect of ramipril on the incidence of diabetes. N Engl J Med, 355:1551-62.
9. Fisher N, Hollenberg N. 2005. Renin inhibition: What are the therapeutic opportunities? J Am Soc Nephro, 16:592-9.
10. Fox KM and European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. 2003. Efficacy on perindopril in reduction of cardiovascular events among patients with stable coronary artery disease randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 362:782-8.
11. Franken AAM, Derkx FHM, Man in't Veld AJ, et al. 1990. High plasma prorenin in diabetes mellitus and its correlation with some complications. J Clin Endocrinol Metab, 71:1008-15.
12. Furuhashi M, Ura N, Higashiura K, et al. 2003. Blockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients with Essential Hypertension. Hypertension, 42:76-81.
13. Griendling KK, Minieri CA, Ollerenshaw JD, et al. 1994. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res, 74:1141-8.
14. Griendling KK, Sorescu D, Ushio-Fukai M. 2000. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res, 86:494-501.
15. Guay DR. 2003. Trandolapril: a newer angiotensin-converting enzyme inhibitor. Clin Ther, 25:713-75.
16. Hansson L, Lindholm LH, Niskanen L, et al. 1999. Effect of angiotensin converting-enzyme inhibition compared with conventional therapy an cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet: 353:611-16.
17. [HOPE] The Heart Outcomes Prevention Evaluation Study Investigators. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med, 342:145-53.
18. Julius S, Kjeldsen S, Weber M, et al. 2003. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet, 363:2022-31.
19. Khan BV, Sola S, Lauten W, et al. 2004. Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care, 27:1712-15.
20. Køber L, Torp-Pedersen C, Carlsen JE, et al. 1995. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 333:1670-6.
21. Kondo J, Sone T, Suboi H, et al. 2003. Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. Am Heart J, 146:1022-7.
22. Kon V, Jabs K. 2004. Angiotensin in atherosclerosis. Curr Opin Nephrol Hypertens, 13:291-7.
23. Krutzfeldt J, Raasch W, Klein HH. 2000. Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol, 362:1-6.
24. Lakka HM, Laaksonen DE, Lakka TA, et al. 2002. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 288:2709-16.
25. Lau DC, Dhillon B, Yan H, et al. 2005. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol, 288: H2031-41.
26. Lindholm LH, Ibsen H, Dahlöf B, et al. 2002. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol. Lancet, 359:1004-10.
27. Lonn E, WeitzJ, DzavikV, et al; forthe SECURE and HOPE Investigators. 2000. Effects of ramipril and vitamin E on hematological markers of fibrinolysis, coagulation and endothelial function: results of the MORE-HOPE study. Can J Cardiol, 16(Suppl F):233F.
28. MacMahon S, Sharpe N, Gamble G, et al. 2000. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol, 36:438-43.
29. Mancini GBJ, Henry GC, Macaya C, et al. 1996. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation, 94:258-65.
30. Miyazaki M, Kawamoto T, Okunishi H. 1995. Vascular affinity of trandolapril. Am J Hypertension, 8:63S-67S.
31. Montagnani M, Golovchenko I, Kim I, et al. 2002. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem, 277:1794-9.
32. Nagamia S, Pandian A, Cheema F, et al. 2007. The role of quinapril in the presence of a weight loss regimen: endothelial function and markers of obesity in patients with the metabolic syndrome. Prev Cardiol. In press.
33. Nissen S, Tuzcu M, Libby P, et al. 2004. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA, 292:2217-25.
34. Nussberger J, Wuerzner G, Jensen C, et al. 2002. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension, 39:1-8.
35. Ortlepp JR, Breuer J, Eitner F, et al. 2002. Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia. Eur J Pharmacol, 436:145-50.
36. [PEACE] The PEACE Trial Investigators. 2004. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med, 35:2058-68.
37. Pfeffer MA, Braunwald E, Moye LA, et al; for the SAVE Investigators. 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction and myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med, 327:669-77.
38. Pfeffer M, McMurray J, Velazquez E, et al. 2003. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med, 349:1893-906.
39. Pfeffer M, Swedberg K, Granger C, et al. 2003. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall program. Lancet, 362:759-66.
40. Pischon T, Girman CJ, Hotamisligil GS, et al. 2004. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA, 291:1730-7.
41. Pitt B. 2004. ACE inhibitors for patients with vascular disease without left ventricular dysfunction-may they rest in peace? N Engl J Med, 351:2115-17.
42. Pitt B, O'Neill B, Feldman R, et al. 2001. The Quinapril Ischemic Event Trial (QUIET) evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol, 87:1058-63.
43. Pollare T, Lithell H, Berne C. 1989. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med, 321:868-73.
44. Pool JL, Schmieder RE, Azizi M, et al. 2007. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens, 20:11-20.
45. Prasad A, Koh KK, Schenke WH, et al. 2001. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am Heart J, 142:248-53.
46. Prasad A, Quyyunri A. 2004. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation, 110:1507-12.
47. Rajagopalan S, Kurz S, Münzel T, et al. 1996. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest, 97:1916-23.
48. Schmidt AM, Yan SD, Wautier JL, et al. 1999. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res, 84:489-97.
49. Shiuchi T, Cui TX, Wu L, et al. 2002. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension, 40:329-34.
50. Skegg LT, Khan JR, Lentz KE, et al. 1957. Preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med, 106:439-53.
51. Stanton A, Jensen C, Nussberger J, et al. 2003. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension, 42:1137-43.
52. Szmitko P, Wang CH, Weisel RD, et al. 2003. Biomarkers of vascular disease linking inflammation to endothelial activation. Circulation, 108:2041-8.
53. Tan K, Chow W, Wong Y, et al. 2002. Effect of losartan on plasma C-reactive protein in type 2 diabetic patients with microalbuminuria. Diabetes Care, 25:1254.
54. The SOLVD Investigators. 1991. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med, 325:293-302.
55. The SOLVD Investigators. 1992. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med, 327:685-91.
56. Tsikouris JP, Cox DC. 2003. Pharmacologic blockade of the renin angiotensin system: vascular benefits beyond commonly understood pharmacologic actions. Pharmacotherapy, 23:1141-52.
57. Velloso LA, Folli F, Sun XJ, et al. 1996. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA, 93:12490-5.
58. Wagner AH, Kohler T, Ruckschloss U, et al. 2000. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol, 20:61-9.
59. Yusuf S. 2002. From the HOPE to the ONTARGET and TRANSCEND studies: challenges in improving prognosis. Am J Cardiol, 89:18A-26A.
60. Yusuf S, Gerstein H, Hoogwerf B, et al. 2001. Ramipril and the development of diabetes. JAMA, 286:1882-5.